Anna Chalmers, MD
Hematology & Oncology · Salt Lake City, UTNPI 1992025787
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Springworks Therapeutics, Inc. at 39.1% of the total.
Across 39 payments — averaging $737.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Springworks Therapeutics, Inc.$11K
- Boehringer Ingelheim$10K
- Daiichi Sankyo Inc.$5K
- Deciphera Pharmaceuticals Inc.$2K
- AstraZeneca$209
- Adaptimmune LLC$93
Across 162 payments — averaging $7705.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$655K
- Boehringer Ingelheim$469K
- Blueprint Medicines Corporation$115K
- Boehringer Ingelheim Pharma GmbH & Co.kg$9K
- Boehringer Ingelheim International GmbH$278
What the payments were for
- Consulting fees$16,92859%
- Speaking & faculty fees$8,80531%
- Travel & lodging$1,9177%
- Food & beverage$1,0894%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Springworks Therapeutics, Inc. | 13 | $11,243 |
| Boehringer Ingelheim | 9 | $10,454 |
| Daiichi Sankyo Inc. | 10 | $4,990 |
| Deciphera Pharmaceuticals Inc. | 3 | $1,792 |
| AstraZeneca | 3 | $209 |
| Adaptimmune LLC | 1 | $93 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OGSIVEO$11,123
- Turalio$4,862
- VIMSELTINIB$1,100
- ROMVIMZA$550
- QINLOCK$142
How this compares
$28,781 in reported general payments places this provider in the 80th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VotrientPazopanib Hcl | 13 | $85,050 |
| Imatinib Mesylate | 11 | $1,056 |
| Ondansetron Hcl | 13 | $235 |
| Dexamethasone | 13 | $195 |
| Prochlorperazine Maleate | 13 | $189 |
| Olanzapine | 12 | $97 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Salt Lake City
- Douglas SborovSalt Lake City$473K
- Daniel CourielSalt Lake City$229K
- Shiven PatelSalt Lake City$223K
- Neeraj AgarwalSalt Lake City$159K
- Benjamin MaughanSalt Lake City$142K
- Schickwann TsaiSalt Lake City$137K
- Heloisa SoaresSalt Lake City$111K
- Daanish HodaSalt Lake City$80K
- Tsewang TashiSalt Lake City$69K
- Finn PetersenSalt Lake City$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.